Credit Suisse analyst Alethia Young also defended Sarepta Therapeutics (NASDAQ: SRPT) amid EXONDYS51 deaths reported in the FDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE